Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading TCRT daily closes…
Loading price history…
Pipeline assets
ALN1003
Preclinical · ActiveModality: Oral small molecule
Indications
Metabolic syndrome and related conditions (obesity, MASLD, insulin resistance)(Preclinical)
Status note Internally developed candidate in the early-preclinical Obesity and Metabolic Disorders Program; company is advancing it through additional studies, formulation optimization and manufacturing scale-up toward IND-enabling activities. Legacy TCR-T assets are subject only to limited ongoing efforts to monetize remaining intellectual property.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.